Xerostomia (Dry Mouth Disease) Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Xerostomia (Dry Mouth Disease) Therapeutics market is projected to register a CAGR of xx% during the forecast period.

The COVID-19 pandemic has posed new challenges in every aspect of our lives, including oral health. Dry mouth has become one of the most common problems that patients from all walks of life are dealing with. COVID-19 has also been linked to dry mouth as a symptom. Dry mouth appeared in 60% of cases 3-4 days before as a prodromal symptom and in others, simultaneously or 1-2 days after the onset of other symptoms, according to a study published in 2021 titled "Xerostomia (dry mouth) in patients with COVID-19: a case series." In the majority of cases, dry mouth improved over time after beginning treatment. In COVID-19, xerostomia may develop prior to the onset of the common symptoms.

Xerostomia, commonly referred to as dry mouth syndrome, is a result of reduced or absent salivary flow producing mucosal dryness. The increase in radiation therapy and chemotherapy is likely to lead to an increased incidence of xerostomia, which is estimated to predominantly drive the xerostomia therapeutics market. Other factors driving the market growth include increasing usage of prescription medicines, easy availability and cost-effectiveness of medicines, growing geriatric population base and increasing prevalence of diseases, such as Sjogren’s syndrome, HIV, diabetes, and Alzheimer’s disease, among other diseases. Moreover, factors, such as lack of awareness and unavailability of effective treatment, is likely to hinder the usage of xerostomia therapeutics products and can act as a restraining factor for the xerostomia therapeutics market.

Key Market Trends

Artificial Saliva/Saliva Substitutes Segment Expected to Dominate the Market Over the Forecast Period

The reduction of saliva in the mouth can lead to tooth decay, mouth infections, an altered sense of taste or smell, difficulty in swallowing, pain, and many other complications. Artificial saliva is a liquid or aerosol product that is sprayed into the mouth. They are designed to moisten and relieve the pain and discomfort from chronic dry mouth, especially with regular use. Many artificial saliva sprays and gels claim to work for up to two hours, and many users require more frequent applications to maintain moisture in the mouth, which can greatly interfere with a good night’s sleep and daily activity. Several saliva sprays and gels also have a reputation for strong and unpleasant flavors, though a recent increase in the use of naturally sweet xylitol has led to the availability of better alternatives. Hence, owing to the aforementioned factors, along with rising disease burden, and availability of over-the-counter artificial saliva products, the segment is expected to register a steady growth during the forecast period.

Asia-Pacific is Expected to be the Fastest Growing Region Over the Forecast Period

The Asia-Pacific region is expected to register a lucrative CAGR over the forecast period due to factors, such as growing healthcare expenditure, an increase in initiatives for raising awareness, and rising prevalence of diseases, such as diabetes, HIV, cancer, and Parkinson’s disease that cause dry mouth conditions. Cancer rates are increasing drastically in the Asia-Pacific region. Owing to rising incomes and better access to childhood vaccinations, the life expectancy in the region is high, which increases health risks related to behavioral factors, in turn resulting in cancer. Emerging economies, such as China and India, have adopted both health and industrial policy for encouraging domestic production of cancer drugs, which is leading to lower therapy costs. Lower therapy costs, coupled with increasing awareness about cancer, is leading to higher adoption of chemotherapy and radiotherapy.

Also, as per the article titled “An Update on the Lived Experience of Dry Mouth in Sjögren's Syndrome Patients” published in November 2021, Dry mouth is a significant condition that impacts on the daily lives of people with Sjögren's Syndrome (SS). As per the same source, In the Sjögren's International Collaborative Clinical Alliance (SICCA) registry of 1578 SS participants, 90% reported symptoms of dry mouth. Furthermore, according to the article titled “Analysis of medication-induced xerostomia in elderly Japanese patients”, published in September 2021, stated that the risk of xerostomia also increases with the age as the number of medications they take tends to increase.

Hence, the increasing prevalence of chronic diseases results in the increased use of medications, thereby resulting in dry mouth. This is likely to boost the demand for products to treat the condition.

Competitive Landscape

Key players in xerostomia (dry mouth disease) therapeutics market are focusing on the development of their product portfolio, acquisition of emerging players, and distribution agreements to increase their geographical presence. Some of the key players dominating the xerostomia therapeutics market are 3M, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Lupin, Parnell Pharmaceuticals Inc, Sun Pharmaceutical Industries Ltd, and Synedgen, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.